Aaron Lazorwitz

Dr. Aaron Lazorwitz

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Contraception
Verified
Journal Article
Closed access
ALAaron Lazorwitz
Aaron Lazorwitz
ADAnne Davis
Anne Davis
MSMaryke Swartz
Maryke Swartz
MGMaryam Guiahi
Maryam Guiahi

1 April 2019 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
ALAaron Lazorwitz
Aaron Lazorwitz
CAChristina L. Aquilante
Christina L. Aquilante
KOKris Bs Oreschak
Kris Bs Oreschak
JSJeanelle Sheeder
Jeanelle Sheeder
MGMaryam Md Guiahi
Maryam Md Guiahi
STStephanie Teal
Stephanie Teal
OBJECTIVE: To identify genetic variants that influence steady-state etonogestrel concentrations among contraceptive implant users. METHODS: We enrolled healthy, reproductive-age women in our pharmacogenomic study using etonogestrel implants for 12–36 months without concomitant use of hepatic enzyme inducers or inhibitors. We collected participant characteristics, measured serum etonogestrel concentrations, and genotyped each participant for 120 single nucleotide variants in 14 genes encoding proteins involved in steroid hormone (ie, estrogens, progestins) metabolism, regulation, or function. We performed generalized linear modeling to identify genetic variants associated with steady-state etonogestrel concentrations. RESULTS: We enrolled 350 women, who had a median serum etonogestrel concentration of 137.4 pg/mL (range 55.8–695.1). Our final generalized linear model contained three genetic variants associated with serum etonogestrel concentrations: NR1I2(PXR) rs2461817 (β=13.36, P=.005), PGR rs537681 (β=−29.77, P=.007), and CYP3A7*1C (β=−35.06, P=.025). Variant allele frequencies were 69.4%, 84.9%, and 5.1%, respectively. Our linear model also contained two nongenetic factors associated with etonogestrel concentrations: body mass index (BMI) (β=−3.08, P=7.0×10−7) and duration of implant use (β=−1.60, P=5.8×10−5); R2 for the model =0.17. CONCLUSION: Only BMI and duration of implant use remained significantly associated with steady-state etonogestrel concentrations. Of the three novel genetic associations found, one variant associated with increased etonogestrel metabolism (CYP3A7*1C) causes adult expression of fetal CYP3A7 proteins and can consequently alter steroid hormone metabolism. Women with this variant may potentially have increased metabolism of all steroid hormones, as 27.8% (5/18) of CYP3A7*1C carriers had serum etonogestrel concentrations that fell below the threshold for consistent ovulatory suppression (less than 90 pg/mL). More pharmacogenomic investigations are needed to advance our understanding of how genetic variation can influence the effectiveness and safety of hormonal contraception, and lay the groundwork for personalized medicine approaches in women's health. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT03092037.

1 October 2019 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
ALAaron Lazorwitz
Aaron Lazorwitz
CAChristina L. Aquilante
Christina L. Aquilante
EDEva Dindinger
Eva Dindinger
MHMargaret Ba Harrison
Margaret Ba Harrison
JSJeanelle Sheeder
Jeanelle Sheeder
STStephanie Teal
Stephanie Teal
OBJECTIVE: To estimate whether serum etonogestrel concentrations influence bleeding patterns and related side effects in contraceptive implant users. METHODS: We conducted a prospective cross-sectional study with healthy, reproductive-aged women using etonogestrel implants for 12–36 months. Participants completed a brief questionnaire to assess their current bleeding pattern and any experience of abnormal bleeding with the implant. We then measured serum etonogestrel concentrations. We also reviewed the charts of participants to determine whether a prescription for oral contraceptive pills was ever given for treatment of implant-related bothersome bleeding. We performed multivariable logistic regression to test for associations between serum etonogestrel concentrations and both bleeding patterns and related side effects. RESULTS: We enrolled 350 women, and 59.4% reported having experienced abnormal bleeding with the contraceptive implant. Only 14.9% of participants reported amenorrhea and 37.7% reported monthly periods. Among participants with reviewable medical records (n=253), roughly 20% had received a prescription for oral contraceptive pills during implant use. Increasing serum etonogestrel concentrations were significantly associated with increasing odds of reporting abnormal bleeding (adjusted odds ratio [aOR] 1.005, P=.015) and increasing odds of having received an oral contraceptive pill prescription (aOR 1.008, P=.002). For every 100 pg/mL increase in serum etonogestrel concentration, contraceptive implant users in this study had 1.6 times the odds of reporting abnormal bleeding and 2.3 times the odds of having received a prescription as treatment for bothersome bleeding. CONCLUSION: We found both objective and subjective evidence that higher levels of progestin from the contraceptive implant were associated with bleeding side effects experienced by women in this study. Pharmacologic variation may influence the side effects women experience with a variety of hormonal contraceptive methods, in turn affecting patient satisfaction and discontinuation rates.

1 July 2019 in Contraception
Verified
Journal Article
Closed access
ALAaron Lazorwitz
Aaron Lazorwitz
CAChristina L. Aquilante
Christina L. Aquilante
JSJeanelle Sheeder
Jeanelle Sheeder
MGMaryam Guiahi
Maryam Guiahi
STStephanie Teal
Stephanie Teal

10 March 2022 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
ALAaron Lazorwitz
Aaron Lazorwitz
MPMorgan Ba Pena
Morgan Ba Pena
JSJeanelle Sheeder
Jeanelle Sheeder
STStephanie Teal
Stephanie Teal
OBJECTIVE: To evaluate topiramate and etonogestrel pharmacokinetic interactions in contraceptive implant users. METHODS: We conducted a prospective, noninferiority study with healthy women using etonogestrel implants continuously for 12–36 months. We measured baseline serum etonogestrel concentrations and then began a 6-week titrated topiramate regimen to standard migraine (100 mg/day) and epilepsy (400 mg/day) dosages. We repeated serum etonogestrel concentrations at 3 weeks (100 mg/day), 4 weeks (200 mg/day), and 6 weeks (400 mg/day) of topiramate therapy. We measured etonogestrel using a validated liquid chromatography-tandem, mass-spectrometry assay and tested for noninferiority (less than 30% decrease) in serum etonogestrel concentrations from baseline. RESULTS: We enrolled 48 total participants; 32 completed 3 weeks, 31 completed 4 weeks, and 27 completed all follow-up visits. Participants' median age was 25.3 years (range 18.3–37.2), median body mass index (BMI) was 25.5 kg/m2 (range 18.7–42.2), and median duration of implant use was 24 months (range 12–36). Median etonogestrel concentrations were 142 pg/mL (range 76.2–771) at baseline, 126 pg/mL (range 72.4–585) at 3 weeks, 119 pg/mL (range 65.6–542) at 4 weeks, and 105 pg/mL (46.2–859) at 6 weeks. The 95% CIs for mean percent change in serum etonogestrel concentrations from baseline were [−37.3%+16.9%], [−45.4%+5.2%], and [−66.8%+24.8%] at 3 weeks, 4 weeks, and 6 weeks, respectively. Excluding one participant who had a serum etonogestrel concentration less than 90 pg/mL at baseline, 30.8% of participants (8/26, 95% CI 14.3–51.8%) had a serum etonogestrel concentration less than 90 pg/mL at 6 weeks. CONCLUSION: Though only a mild enzyme-inducing antiepileptic drug, concomitant topiramate use led to inferior serum etonogestrel concentrations among implant users, with a significant proportion reaching etonogestrel concentrations below the threshold for ovulatory suppression when taking antiepileptic dosages of topiramate. FUNDING SOURCE: This study was primarily funded through an Investigator-Initiated Study grant from Merck Sharp & Dohme Corp [MISP#57073]. This work was also supported by NIH/NCATS CTSA Grant Number UL1 TR001082 and NICHD K12 Women's Reproductive Health Research Scholar Program (grant number 5K12HD001271-18). CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT03335163.

12 May 2020 in Contraception
Verified
Journal Article
Closed access
ALAaron Lazorwitz
Aaron Lazorwitz
EDEva Dindinger
Eva Dindinger
MHMargaret Harrison
Margaret Harrison
CAChristina L. Aquilante
Christina L. Aquilante
JSJeanelle Sheeder
Jeanelle Sheeder
STStephanie Teal
Stephanie Teal